Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaLisa Zimmer, Dirk Schadendorf, Julia Vaübel et al.|PLoS ONE|2015Cited by 292
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazineJean‐Jacques Grob, Axel Hauschild, Patricia Haney et al.|Annals of Oncology|2014Cited by 55
Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.Lisa Zimmer, Dirk Schadendorf, Thomas Eigentler et al.|Journal of Clinical Oncology|2014Cited by 8